Oncology and Hematology
385-400 of 612
- MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
1.00 program credit
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Charles Turck, PharmD, BCPS, BCCCP
Hannah McManus, MD
Andrew Armstrong, MD, MSc
Joyce O'Shaughnessy, MD
Daniel Kwon, MD
Sarah Sammons, MD
Sarah Sammons, MD
- Project Oncology®
Emerging Metastatic Breast Cancer Therapies: From CDK Inhibitors to SERDs and Beyond
Sarah Sammons, MD
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
1.25 program creditsHope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Nadia Harbeck, MD, PhD
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program creditsHope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Nadia Harbeck, MD, PhD
